Docoh
Loading...

MYGN Myriad Genetics

Employees

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM



On June 3, 2021, Myriad Genetics, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 77,000,430 shares of Company common stock outstanding as of the record date of April 8, 2021, a quorum of 69,290,013 shares, or approximately 89.98% of the outstanding shares of Company common stock, was present in person (via webcast) or represented by proxy.




The following is a brief description of each matter submitted to a vote at the Annual Meeting, as well as the number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter.




Proposal No. 1: Election of Directors




To elect S. Louise Phanstiel, Daniel M. Skovronsky, M.D., Ph.D., and Daniel K. Spiegelman to serve until the 2024 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, retirement or removal.







Votes
For
Votes
Against
Votes
Abstained
Broker
Non-Votes
S. Louise Phanstiel59,900,4494,190,30620,5095,178,749
Daniel M. Skovronsky, M.D., Ph.D.63,765,877330,70514,6825,178,749
Daniel K. Spiegelman63,380,731705,36125,1725,178,749





Proposal No. 2: Ratification of the Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2021




Votes
For
Votes
Against
Votes
Abstained
67,469,4741,810,6169,923





Proposal No. 3: Approval, on an Advisory Basis, of the Compensation of Our Named Executive Officers, as Disclosed in the Proxy Statement







Votes
For
Votes
Against
Votes
Abstained
Broker
Non-Votes
62,380,2201,697,82933,2155,178,749